Consensus Lupin Limited

Stocks

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:25:11 17/06/2026 BST			5-day change	1st Jan Change
2,266.80 ^INR	-0.45%		+0.15%	+7.33%

01:51pm	Lupin Limited Launches Azilsartan Medoxomil Tablets in the United States	CI
06-08	Lupin Teams Up with Laboratorios ERN for Asthma, COPD Drug Launch in Spain	MT

Evolution of the Average Target: Lupin Limited

Evolution of the Target Price: Lupin Limited

Changes in Analyst Recommendations: Lupin Limited

dca377367564d8.rU904AtIvw0ptD_mZ5VUVDMrp0zmk7DcNjsHfbl1oNE.wBYyiloG7TlewHexM-c5Hngc_ijWqoKtYVVWBPcwxZCbKz-BUyDgQkDQZg~200d105879300f45856f9da763587d03

Analysts' recommendations: Lupin Limited

05-13	Nomura Adjusts Lupin's Price Target to INR2,675 From INR2,580, Keeps at Buy	MT
05-11	Emkay Global Downgrades Lupin to Add from Buy; Price Target is INR2,500	MT
05-11	Phillip Securities Downgrades Lupin to Neutral from Buy; Price Target is INR2,420	MT
05-11	JM Financial Downgrades Lupin to Sell from Reduce; Price Target is INR1,992	MT
05-11	Jefferies Downgrades Lupin to Underperform from Buy, Adjusts Price Target to INR2,020 from INR2,540	MT
02-16	Jefferies Adjusts Lupin's Price Target to INR2,540 From INR2,430, Keeps at Buy	MT
11-11	Nomura Adjusts Lupin's Price Target to INR2,580 From INR2,350, Keeps at Buy	MT
11-10	Jefferies Adjusts Lupin's Price Target to INR2,300 From INR2,250, Keeps at Buy	MT
11-10	Avendus Spark Upgrades Lupin to Buy from Add; Price Target is INR2,270	MT
07/08/25	Jefferies Upgrades Lupin to Buy From Hold, Adjusts Price Target to INR2,250 From INR2,200	MT
13/02/25	Jefferies Adjusts Lupin's Price Target to INR2,200 From INR2,400, Keeps at Hold	MT
13/02/25	Nomura Adjusts Lupin's Price Target to INR2,350 From INR2,490, Keeps at Buy	MT
11/11/24	Jefferies Adjusts Lupin's Price Target to INR2,070 From INR1,900, Keeps at Hold	MT
11/11/24	Nomura Adjusts Lupin's Price Target to INR2,490 From INR2,427, Keeps at Buy	MT
11/11/24	Nomura Adjusts Lupin's Price Target to INR2,490 From INR2,427, Keeps at Buy	MT
30/08/24	Nomura Adjusts Lupin's Price Target to INR2,427 From INR1,952, Keeps at Buy	MT
08/08/24	Jefferies Adjusts Lupin's Price Target to INR1,900 From INR1,535, Keeps at Hold	MT
09/05/24	Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	MT
08/05/24	Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold	MT
09/02/24	Jefferies Upgrades Lupin to Hold From Underperform, Adjusts Price Target to INR430 From INR520	MT
02/01/24	Nomura Adjusts Lupin's Price Target to INR1,593 From INR1,290, Keeps at Buy	MT
08/08/23	Nomura Adjusts Lupin’s Price Target to INR1,290 From INR977, Keeps at Buy	MT
07/08/23	Jefferies Adjusts Lupin’s Price Target to INR810 From INR660, Keeps at Underperform	MT
26/06/23	Nomura Adjusts Lupin's Price Target to INR977 From INR861, Keeps at Buy	MT
12/05/23	Nomura Adjusts Lupin's Price Target to INR861 From INR856, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LUPIN LIMITED					+8.32%
	ELI LILLY AND COMPANY					+8.31%
	JOHNSON & JOHNSON					+7.52%
	ABBVIE INC.					+13.97%
	ROCHE HOLDING AG					+11.35%
	NOVARTIS AG					+2.68%
	ASTRAZENECA PLC					+23.98%
	NOVO NORDISK A/S					+11.23%
	AMGEN INC.					+1.42%
	GILEAD SCIENCES, INC.					+23.85%
	Average					+11.26%
	Weighted average by Cap.					+10.46%